A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

This study is testing a new experimental drug called BBO-11818, which is designed to block a specific genetic change called 'KRAS' that helps certain cancers grow. It matters because it aims to find a new, safer way to treat advanced cancers of the lung, pancreas, and colon that haven't responded to other therapies.

You may be eligible if you have an advanced KRAS-mutant cancer that cannot be removed by surgery or has spread to other parts of your body. Participants must be generally active, have stable organ function, and have tumors that doctors can clearly track with medical scans.

As this is a Phase 1 study, researchers are primarily monitoring your safety while receiving the experimental treatment. You will have regular check-ups and medical scans to see how your body handles the drug and whether it helps shrink your tumors.

The study is currently recruiting patients at research centers in Los Angeles, Sacramento, and San Diego, California. You should talk to your doctor to see if one of these locations is right for you.